Please assess the completion status of the following clinical trial:

Trial Title: 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for allogeneic HCT, independent of age~* Adult patients of any age with a cytopathologically confirmed diagnosis according to WHO classification of newly diagnosed AML (not APL = AML-M3), de novo AML or secondary AML~* in first complete remission (CR1)~* Poor risk or very poor risk subgroups~* WHO performance status ≤ 2~* Written informed consent~Exclusion Criteria:~* Patient not in CR1~* Patients who have senile dementia, mental impairment of any other psychiatric disorder that prohibits the patient from understanding and giving informed consent~* Active serious infections like HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV)~* Patient is unwilling to use contraceptive techniques during and for 12 months following treatment~* Female patient who is pregnant or breastfeeding~* Active and uncontrolled infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).